Characterization of a conjugated polysuccinimide-carboplatin compound
暂无分享,去创建一个
M. Zrínyi | Xiangguo Che | Je-Yong Choi | Sun Young Lee | C. Chae | D. Cho
[1] P. Kesharwani,et al. Dendrimer as a promising nanocarrier for the delivery of doxorubicin as an anticancer therapeutics , 2021, Journal of biomaterials science. Polymer edition.
[2] J. Nemunaitis,et al. Ovarian Cancer Immunotherapy and Personalized Medicine , 2021, International journal of molecular sciences.
[3] E. Pollet,et al. Biological properties of novel polysuccinimide derivatives synthesized via quaternary ammonium grafting , 2020 .
[4] Michal Kielbik,et al. The Potential Role of iNOS in Ovarian Cancer Progression and Chemoresistance , 2019, International journal of molecular sciences.
[5] M. Zrínyi,et al. Kinetics of dopamine release from poly(aspartamide)-based prodrugs. , 2018, Acta biomaterialia.
[6] R. Jove,et al. Ruxolitinib synergistically enhances the anti-tumor activity of paclitaxel in human ovarian cancer , 2018, Oncotarget.
[7] J. Ledermann,et al. Front-line therapy of advanced ovarian cancer: new approaches , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] V. Vinokurov,et al. Paclitaxel Encapsulated in Halloysite Clay Nanotubes for Intestinal and Intracellular Delivery. , 2017, Journal of pharmaceutical sciences.
[9] M. Potara,et al. Carboplatin-Loaded, Raman-Encoded, Chitosan-Coated Silver Nanotriangles as Multimodal Traceable Nanotherapeutic Delivery Systems and pH Reporters inside Human Ovarian Cancer Cells. , 2017, ACS applied materials & interfaces.
[10] H. Tajmir-Riahi,et al. Review on the targeted conjugation of anticancer drugs doxorubicin and tamoxifen with synthetic polymers for drug delivery , 2017, Journal of biomolecular structure & dynamics.
[11] Guojun Chen,et al. Carboplatin-Complexed and cRGD-Conjugated Unimolecular Nanoparticles for Targeted Ovarian Cancer Therapy. , 2017, Macromolecular bioscience.
[12] S. Jordan,et al. Epidemiology of epithelial ovarian cancer. , 2017, Best practice & research. Clinical obstetrics & gynaecology.
[13] R. Burger,et al. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] Thomas A. Sellers,et al. Epidemiology of ovarian cancer: a review , 2017, Cancer biology & medicine.
[15] J. Coward,et al. Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies. , 2016, Critical reviews in oncology/hematology.
[16] Robert Langer,et al. Emerging Frontiers in Drug Delivery , 2016 .
[17] Anjali Jain,et al. Biodegradable polymers for targeted delivery of anti-cancer drugs , 2016, Expert opinion on drug delivery.
[18] K. Lisowska,et al. [Ovarian cancer--from biology to clinic]. , 2015, Postepy higieny i medycyny doswiadczalnej.
[19] I. Joye,et al. Biopolymer-Based Delivery Systems: Challenges and Opportunities. , 2015, Current topics in medicinal chemistry.
[20] D. Brooks,et al. Biodegradable polyglycerols with randomly distributed ketal groups as multi-functional drug delivery systems. , 2013, Biomaterials.
[21] B. Kong,et al. Topotecan plus carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a meta-analysis of randomized controlled trials , 2012, Journal of chemotherapy.
[22] M. Zrínyi,et al. Kinetics of volume change of poly(succinimide) gels during hydrolysis and swelling. , 2010, Physical chemistry chemical physics : PCCP.
[23] C. Rao. Nitric oxide signaling in colon cancer chemoprevention. , 2004, Mutation research.
[24] Bernhard Brüne,et al. Nitric oxide: NO apoptosis or turning it ON? , 2003, Cell Death and Differentiation.
[25] Suyun Huang,et al. Contribution of nitric oxide-mediated apoptosis to cancer metastasis inefficiency. , 2003, Free radical biology & medicine.
[26] R. Coleman. Emerging role of topotecan in front-line treatment of carcinoma of the ovary. , 2002, The oncologist.
[27] P. Hainaut,et al. Nitric oxide nitrates tyrosine residues of tumor-suppressor p53 protein in MCF-7 cells. , 2000, Biochemical and biophysical research communications.
[28] T. Billiar,et al. Nitric oxide reversibly inhibits seven members of the caspase family via S-nitrosylation. , 1997, Biochemical and biophysical research communications.
[29] N. Pavlidis,et al. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study. , 1997, Seminars in oncology.
[30] B. Brüne,et al. Nitric oxide-induced apoptosis: p53-dependent and p53-independent signalling pathways. , 1996, The Biochemical journal.
[31] C. Harris,et al. Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[32] P Rhodes,et al. Roles of nitric oxide in tumor growth. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[33] P. Couvreur,et al. [Polymer nanoparticles for the delivery of anticancer drug]. , 2017, Medecine sciences : M/S.
[34] H. Hamishehkar,et al. Synthesis of a novel superdisintegrant by starch derivatization with polysuccinimide and its application for the development of Ondansetron fast dissolving tablet. , 2016, Drug development and industrial pharmacy.